Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021
Yihui Song, Huiqing Zhang, Xiaoke Yang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 228, pp. 114042-114042
Closed Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Discovery of novel dual-target inhibitors of LSD1/EGFR for non-small cell lung cancer therapy
Yu Wei, Mingming Sun, Ruili Zhang, et al.
Acta Pharmacologica Sinica (2025)
Open Access | Times Cited: 1
Berberine as a potential agent for breast cancer therapy
Xiao-Dan Zhong, Lijuan Chen, Xin-Yang Xu, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 41
Histone demethylases in the regulation of immunity and inflammation
Lihua Qu, Tong Yin, Yijin Zhao, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 26
Leveraging non-enzymatic functions of LSD1 for novel therapeutics
Yihui Song, Bin Yu
Trends in Pharmacological Sciences (2025)
Closed Access
Targeting epigenetic regulators for inflammation: Mechanisms and intervention therapy
Su Zhang, Yang Meng, Lian Zhou, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 31
Lysine-Specific Demethylase 1 Inhibitors: A Comprehensive Review Utilizing Computer-Aided Drug Design Technologies
Di Han, Jiarui Lu, Baoyi Fan, et al.
Molecules (2024) Vol. 29, Iss. 2, pp. 550-550
Open Access | Times Cited: 6
Ldha Accelerates Primary Cisplatin Resistance in Lung Adenocarcinoma by Modulating Ambra1 Ubiquitination Via Moonlighting Functions
Fengguo Xu, Qiang Wang, Ying Zhang, et al.
(2025)
Closed Access
JBI-802: the first orally available LSD1/HDAC6 dual inhibitor to enter clinical trials
Jingya Zhang, Xiangli Ren, Yihui Song, et al.
Expert Opinion on Therapeutic Patents (2025)
Closed Access
Phenothiazine-Based LSD1 Inhibitor Promotes T-Cell Killing Response of Gastric Cancer Cells
Xing‐Jie Dai, Lijuan Zhao, Longhua Yang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 6, pp. 3896-3916
Closed Access | Times Cited: 13
Strategies that regulate LSD1 for novel therapeutics
Meng Li, Mengge Dai, Bingchuan Cheng, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 4, pp. 1494-1507
Open Access | Times Cited: 4
A state-of-the-art review on LSD1 and its inhibitors in breast cancer: Molecular mechanisms and therapeutic significance
Guan‐Jun Yang, Yanjun Liu, Lijian Ding, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 20
Recent advances of LSD1/KDM1A inhibitors for disease therapy
Chaofeng Zhang, Zhiyuan Wang, Yuting Shi, et al.
Bioorganic Chemistry (2023) Vol. 134, pp. 106443-106443
Closed Access | Times Cited: 11
Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer
Milan Beljkaš, Aleksandra Ilić, Alen Cebzan, et al.
Pharmaceutics (2023) Vol. 15, Iss. 11, pp. 2581-2581
Open Access | Times Cited: 10
Discovery of natural product-like spirooxindole derivatives as highly potent and selective LSD1/KDM1A inhibitors for AML treatment
Chao Yang, Yuan Fang, Xiang Luo, et al.
Bioorganic Chemistry (2022) Vol. 120, pp. 105596-105596
Closed Access | Times Cited: 17
Structural and Functional Landscape of FAD-Dependent Histone Lysine Demethylases for New Drug Discovery
Yihui Song, Shu Wang, Bin Yu
Journal of Medicinal Chemistry (2022) Vol. 66, Iss. 1, pp. 71-94
Closed Access | Times Cited: 15
PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?
Clemens Zwergel, Rossella Fioravanti, Antonello Mai
Drug Discovery Today (2022) Vol. 28, Iss. 2, pp. 103435-103435
Closed Access | Times Cited: 14
Novel acridine-based LSD1 inhibitors enhance immune response in gastric cancer
Xing‐Jie Dai, Ying Liu, Ning Wang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115684-115684
Closed Access | Times Cited: 8
Research progress of LSD1-based dual-target agents for cancer therapy
Xiaojuan Yang
Bioorganic & Medicinal Chemistry (2024) Vol. 101, pp. 117651-117651
Closed Access | Times Cited: 2
The Mendelian disorders of chromatin machinery: Harnessing metabolic pathways and therapies for treatment
Sarah Donoghue, Jordan L. Wright, Anne K. Voss, et al.
Molecular Genetics and Metabolism (2024) Vol. 142, Iss. 1, pp. 108360-108360
Open Access | Times Cited: 2
Tackling drug resistance in ovarian cancer with epigenetic targeted drugs
Lin Zhao, Hongjie Guo, Xi Chen, et al.
European Journal of Pharmacology (2022) Vol. 927, pp. 175071-175071
Closed Access | Times Cited: 13
Stilbenes: a promising small molecule modulator for epigenetic regulation in human diseases
Jing Tian, Jin Li, Hongquan Liu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 7
Exploring the potential of histone demethylase inhibition in multi-therapeutic approaches for cancer treatment
Deping Li, Hailiu Liang, Yifei Wei, et al.
European Journal of Medicinal Chemistry (2023) Vol. 264, pp. 115999-115999
Closed Access | Times Cited: 6
Antagonistic action of GPS2 and KDM1A at enhancers governs alternative macrophage activation by interleukin 4
Zhiqiang Huang, Astradeni Efthymiadou, Ning Liang, et al.
Nucleic Acids Research (2023) Vol. 51, Iss. 3, pp. 1067-1086
Open Access | Times Cited: 5
A Structure–Activity Relationship Study of SNAIL1 Peptides as Inhibitors of Lysine-Specific Demethylase 1
Yuri Takada, Kyohei Adachi, Yuka Fujinaga, et al.
Chemical and Pharmaceutical Bulletin (2024) Vol. 72, Iss. 2, pp. 155-160
Open Access | Times Cited: 1
Histone deacetylase 6 as a novel promising target to treat cardiovascular disease
Ya‐Xi Wu, Bing‐Qian Li, Xiaoqian Yu, et al.
Cancer Innovation (2024) Vol. 3, Iss. 3
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top